Incyte discontinues Jakafi trials in solid tumors

Incyte Corp. (NASDAQ:INCY) reported 4Q15 and 2015 revenues that beat expectations but fell $6.80 to $65.51 on Thursday after it said it would discontinue all ongoing trials of myelofibrosis drug Jakafi ruxolitinib in solid tumors, including the Phase III JANUS 1 and

Read the full 423 word article

User Sign In